Menu Search
Equities

Quantum Genomics SA

2QG:FRA

Quantum Genomics SA

Actions
  • Price (EUR)0.068
  • Today's Change0.00 / 0.00%
  • Shares traded39.78k
  • 1 Year change-33.46%
  • Beta--
Data delayed at least 15 minutes, as of Oct 24 2024 08:51 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Quantum Genomics SA is a France-based company. The Company is a biopharmaceutical company dedicated to developing new therapies for unmet medical needs in cardiovascular disease, including high blood pressure and heart failure. Its main activity is in research and development of new therapies for the treatment of hypertension, BAPAI (Brain Aminopeptidase A Inhibitors) oriented in the field of cardiovascular diseases, especially high blood pressure and heart failure. The Company also co-develops products with academic teams, biotechnological research entities, and some of the pharmaceutical and bio-science companies. The Company is involved in four research programs. Quantum Genomics also collaborates with Center for Clinical Investigation 9201 APHP / INSERM of the Georges Pompidou European Hospital in Paris, among others.

  • Revenue in EUR (TTM)0.00
  • Net income in EUR-9.40m
  • Incorporated2005
  • Employees3.00
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		ALQGC:PAR since
announced		Transaction
value
Exactcure SASAnnounced18 Dec 202318 Dec 2023Announced-34.45%--
Data delayed at least 15 minutes, as of Oct 24 2024 16:35 BST.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.